Navigation Links
First Patient Dosed in Phase I Clinical Trial of Tigris Pharmaceuticals' GGTI-2418
Date:5/1/2009

is reached.

Tigris in-licensed the exclusive worldwide rights to GGTI-2418 from Yale University and the University of South Florida. Said M. Sebti, Ph.D., Director of the Drug Discovery Program at the Moffitt Cancer Center and Andrew Hamilton, Ph.D., Professor of Chemistry at Yale University were the co-inventors of GGTI-2418.

About GGTI-2418

GGTI-2418 is a synthetic peptidomimetic inhibitor of GGTase I that appears to induce apoptosis by downregulating several pivotal oncogenic and tumor survival pathways. GGTase I catalyzes the lipid posttranslational modification which is required for the function of Rho GTPases (frequently found aberrantly activated in human cancer). GGTase I inhibitors block Rho function in cancer cells and induce a G1 phase cell cycle arrest by a mechanism involving induction of the CDK inhibitors p21waf and p27kip, CDK2 and CDK4 inhibition and hypophoshorylation of the tumor suppressor Rb. GGTase I inhibitors also induce apoptosis by a mechanism involving downregulation of the expression of survivin and suppression of the activation of PI3K/Akt.

About Tigris Pharmaceuticals, Inc.

Tigris Pharmaceuticals, Inc. is a privately held biopharmaceutical company that develops therapeutic technologies, using a translational research approach, for use in oncology and other areas of unmet medical need. Tigris' mission is to efficiently move its existing and future technologies through the various stages of clinical development in order to meet patients' needs for safe and effective treatments of human illnesses.

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, st
'/>"/>

SOURCE Tigris Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
3. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
4. Genmab Announces 2007 First Half Year Results
5. Pharsight Achieves First License Sale for Public-Source Database
6. Novare Announces First Ever Single Port Laparoscopic Kidney Removal (Nephrectomy) Using RealHand(TM) HD Instruments
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. China Medical Technologies Reports First Quarter Financial Results
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
11. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... , Aug. 4, 2015 Trigemina, Inc., a ... non-narcotic, nasally delivered, analgesic drug products, announced today that ... the position of chief medical officer. Dr. Kori brings ... much of which has been focused in the neuroscience ... add Dr. Kori to our clinical team given his ...
(Date:8/4/2015)... , ... August 04, 2015 , ... On August 4, ... a diverse selection of entrepreneurs from across the United States to talk about their ... is honored to be chosen to be among the attendees. , One of the ...
(Date:8/3/2015)... 2015 At the 11th hour, ... waved the shortfall of Jude Liversage,s campaign ... the first time.      (Photo: http://photos.prnewswire.com/prnh/20150803/254228 ... ) The Selective Dorsal Rhizotomy (SDR) procedure ... carry out his wish to kick a ball around ...
(Date:8/3/2015)... SAN DIEGO , Aug. 3, 2015  Aethlon Medical, ... affinity biofiltration devices to treat life-threatening diseases, today announced ... investor conference call and webcast on Thursday, August 13, ... call and webcast will follow the release of fiscal ... call will be available approximately two hours after the ...
Breaking Biology Technology:Trigemina Appoints Dr. Shashi Kori to the Position of Chief Medical Officer 2Trigemina Appoints Dr. Shashi Kori to the Position of Chief Medical Officer 3White House Invites uBiome CEO Jessica Richman to First-Ever Startup Demo Day 2Cerebral Palsy Operation by The Portland Hospital Allows a Boy to Stand Properly for the First Time 2Cerebral Palsy Operation by The Portland Hospital Allows a Boy to Stand Properly for the First Time 3Aethlon Medical To Host First Quarter Fiscal 2016 Investor Call on August 13, 2015 2
... - ARIUS Research Inc., (TSX:,ARI), a biotechnology company ... today announced its financial and operational,results for the ... third quarter of fiscal 2007 was one of ... candidate AR001 into human clinical trials in,2008, while ...
... Supplement Far Surpasses ConsumerLab.com Quality Standards, HOFFMAN ... the 78% of consumer products which failed quality ... supplement milk thistle sold by CNCA, a leading ... immune system function,and promote general health and wellness., ...
... 12 Campbell Alliance, the leading,management consulting firm ... that Ben Bonifant, Vice President,of the firm,s Business ... Licensing Executive Society (LES) Annual Meeting. The,event will ... Vancouver Convention and,Exhibit Centre in Vancouver, Canada. ...
Cached Biology Technology:ARIUS Announces Third Quarter Fiscal 2007 Financial Results 2ARIUS Announces Third Quarter Fiscal 2007 Financial Results 3ARIUS Announces Third Quarter Fiscal 2007 Financial Results 4ARIUS Announces Third Quarter Fiscal 2007 Financial Results 5ARIUS Announces Third Quarter Fiscal 2007 Financial Results 6ARIUS Announces Third Quarter Fiscal 2007 Financial Results 7ARIUS Announces Third Quarter Fiscal 2007 Financial Results 8ARIUS Announces Third Quarter Fiscal 2007 Financial Results 9ARIUS Announces Third Quarter Fiscal 2007 Financial Results 10ARIUS Announces Third Quarter Fiscal 2007 Financial Results 11ARIUS Announces Third Quarter Fiscal 2007 Financial Results 12ARIUS Announces Third Quarter Fiscal 2007 Financial Results 13ARIUS Announces Third Quarter Fiscal 2007 Financial Results 14ARIUS Announces Third Quarter Fiscal 2007 Financial Results 15CNCA Exceeds Standards in Nutritional Supplement Quality, Protects Public 2CNCA Exceeds Standards in Nutritional Supplement Quality, Protects Public 3Campbell Alliance Business Development Practice to Moderate Two Workshops at LES Annual Meeting in Vancouver 2Campbell Alliance Business Development Practice to Moderate Two Workshops at LES Annual Meeting in Vancouver 3
(Date:7/8/2015)... , July 8, 2015  Trovagene, Inc. ... molecular diagnostics, today announced the launch of a ... Company,s Precision Cancer Monitoring℠ (PCM) technology for predicting ... one or a combination of the novel immunotherapy ... (nivolumab), a PD-1 inhibitor. The 50-patient study will ...
(Date:7/7/2015)... Conn. , July 7, 2015 NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market announces a revised version ... this week. The commercial will air on CNBC in ... Los Angeles and San Francisco ... The commercial focuses on Wocket,s ability to replace all the cards ...
(Date:6/30/2015)... , June 30, 2015 To bolster its ... provider HYPR Corp. announced today the addition of two new ... serve as board advisor and David Raviv will ... team underscore HYPR Corp.,s commitment to providing the most secure ... Dimitri Sirota co-founded Layer 7 Technologies, a provider of ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
... WASHINGTON -- The National Academy of Sciences (NAS) will ... scientific achievements in the areas of biology, chemistry, geology, ... JOHN ALROY, associate researcher at the National Center ... California, Santa Barbara, is the recipient of the NAS ...
... Householders in the UK should be looking beyond their ... to scientists at the University of Leeds. To ... to create a network of interlinking habitats where birds, ... in isolation, they link together to form interconnected habitat ...
... has documented that Yasun National Park, in the core of ... of plant and animal groups, from amphibians to trees to ... development projects represent the greatest threat to Yasun and its ... most diverse area in South America, and possibly the world," ...
Cached Biology News:NAS honors 17 for major contributions to science 2NAS honors 17 for major contributions to science 3NAS honors 17 for major contributions to science 4NAS honors 17 for major contributions to science 5Gardeners must unite to save Britain's wildlife 2Scientists identify Ecuador's Yasuni National Park as one of most biodiverse places on earth 2
Derlin-2 (C-18)...
CBF-B (G-2)...
Mouse monoclonal [164-12-2] to Ampicillin ( Abpromise for all tested applications)....
Flotillin-2 (ESA) Purified Anti-Mouse, Anti-Rat, Anti-Human, Anti-Dog, Anti-Chicken clone 29, Isotype Mouse IgG 1 , 150 µg Consult technical datasheet for details....
Biology Products: